Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center of China

Next Previous
Trial Profile

Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center of China

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Abiraterone (Primary) ; Alpelisib (Primary) ; Anastrozole (Primary) ; Bevacizumab (Primary) ; Bicalutamide (Primary) ; Cadonilimab (Primary) ; Camrelizumab (Primary) ; Carboplatin (Primary) ; Catequentinib (Primary) ; Cisplatin (Primary) ; Disitamab vedotin (Primary) ; Enfortumab vedotin (Primary) ; Entrectinib (Primary) ; Erlotinib (Primary) ; ESG 401 (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Fuzuloparib (Primary) ; Iparomlimab (Primary) ; Larotinib (Primary) ; Larotrectinib (Primary) ; Letrozole (Primary) ; Leuprorelin (Primary) ; Niraparib (Primary) ; Olaparib (Primary) ; Paclitaxel (Primary) ; Palbociclib (Primary) ; Pamiparib (Primary) ; Pertuzumab (Primary) ; Pyrotinib (Primary) ; Rivoceranib (Primary) ; Sacituzumab govitecan (Primary) ; Sacituzumab Tirumotecan (Primary) ; Toripalimab (Primary) ; Trastuzumab (Primary) ; Tuvonralimab (Primary) ; Vedolizumab (Primary)
  • Indications Carcinoma; Salivary gland cancer
  • Focus Therapeutic Use

Most Recent Events

  • 11 Sep 2025 Protocol has been amended to include new experimental arms, it has been changed from 12 to 19.
  • 11 Sep 2025 Planned End Date changed from 10 Jul 2026 to 10 Jul 2028.
  • 11 Sep 2025 Planned number of patients changed from 10 to 39.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top